Melissa O'Neal

Dr. Melissa O'Neal


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Therapeutic Advances in Infectious Disease
Verified
Journal Article
Open access
PDF file
MOMelissa O'Neal
Melissa O'Neal
HMHanna Murray
Hanna Murray
SDSangita Dash
Sangita Dash
MAMajdi N. Al-Hasan
Majdi N. Al-Hasan
JJJulie Ann Justo
Julie Ann Justo
P. Brandon BookstaverP. Brandon Bookstaver
P. Brandon Bookstaver
This single-center, retrospective, observational cohort study evaluates the appropriateness of the BioFire® FilmArray® Gastrointestinal (GI) multiplex PCR panel testing at a community-teaching hospital. All adult, hospitalized patients at Prisma Health Richland Hospital with a documented GI multiplex PCR panel from 1 April 2015 through 28 February 2018 were included in the analysis. Inappropriate use of the GI panel was defined as a test obtained without documented diarrhea, greater than 2 days of hospitalization, redundant use with other diagnostic tests (e.g. Clostridioides difficile PCR), or laxative use in the preceding 48 h. Antibiotic use and host variables were compared between groups with positive and negative results. During the study period, 442 GI panels were obtained, among which 268 (61%) were deemed inappropriate. Primary reasons for inappropriate testing were lack of documented diarrhea (n = 92), greater than 2 days of hospitalization (n = 116), having a duplicate C. difficile PCR test ordered (n = 118), or laxative use in the 48 h before testing (n = 36). A total of 141 (32%) GI panels were positive. The most frequently identified pathogens were C. difficile (51.1%, n = 72), Enteropathogenic Escherichia coli (17.7%, n = 25), and Norovirus GI/GII (12.1%, n = 17). Patients with negative GI panel results were initiated on antibiotics significantly less frequently than those with positive GI panels (62.5% versus 80.2%, p < 0.00001). Stewardship opportunities exist to optimize the diagnostic application of the GI multiplex PCR panel.

14 July 2022 in Case Reports in Infectious Diseases
Verified
Journal Article
Open access
PDF file
MOMelissa O'Neal
Melissa O'Neal
CLCaitlin E. Labay
Caitlin E. Labay
JHJesse E. Harris
Jesse E. Harris
WMWilliam L. Musick
William L. Musick
PCPatricia L. Cernoch
Patricia L. Cernoch
ERElizabeth Ramos-Salazar
Elizabeth Ramos-Salazar
The bacterial genus Myroides, like other members of the Flavobacteriaceae family, consists of aerobic, non-motile, Gram-negative bacilli. Myroides spp. is considered predominantly opportunistic pathogens as, historically, most documented infections have been in immunocompromised individuals. Along with advancements in molecular assay testing, there are growing reports of clinically relevant Myroides spp. infections in immunocompetent individuals. These organisms display broad antimicrobial resistance, and while research into their mechanisms of resistance is progressing, genetic testing has revealed metallo-β-lactamases present in their genome. The sporadic identification of Myroides spp. and ongoing clarification of resistance patterns make empiric treatment difficult. This report documents two cases of extensively drug-resistant Myroides odoratus isolated from critically ill but otherwise immunocompetent patients followed by a review of available literature on Myroides spp. antibiotic sensitivities. Our findings indicate that minocycline and moxifloxacin have the highest documented in vitro activity against Myroides spp.

6 December 2021 in Case Reports in Transplantation
Verified
Journal Article
Open access
PDF file
TETaryn Ashley Eubank
Taryn Ashley Eubank
CMConstance M. Mobley
Constance M. Mobley
MMMozhgon Moaddab
Mozhgon Moaddab
MHMark J. Hobeika
Mark J. Hobeika
MOMelissa O'Neal
Melissa O'Neal
KGKevin A. Grimes
Kevin A. Grimes
Mucormycosis is caused by ubiquitous fungi and encompasses a variety of different opportunistic syndromes in humans that disproportionately affect immunocompromised patients. Mortality has been documented to range between 50 and 100; however, location of infection greatly dictates likelihood of survival. Treatment of mucormycosis involves aggressive surgical intervention and combination therapy of antifungal agents. In solid organ transplant recipients, immunosuppressive agents used to prevent rejection of the transplanted organ pose additional obstacles in the treatment of invasive fungal infections. We report on 3 high models for end-stage liver disease (MELD-Na) score orthotopic liver transplant (OLT) recipients who all were diagnosed with Rhizopus spp. infections with positive, 1-year outcomes after aggressive, individualized treatment.

28 June 2023 in Transplant Infectious Disease
Verified
Journal Article
Closed access
KGKristen Greene
Kristen Greene
Nick (Nicholas) PiccicaccoNick (Nicholas) Piccicacco
Nick (Nicholas) Piccicacco
MOMelissa O'Neal
Melissa O'Neal
JMJose Montero
Jose Montero
AMAndrew Myers
Andrew Myers
KKKami Kim
Kami Kim

11 February 2026 in Pharmacy
Verified
Journal Article
Open access
PDF file
PKParker Kaleo
Parker Kaleo
NPNatt Patimavirujh
Natt Patimavirujh
KGKristen Greene
Kristen Greene
Nick (Nicholas) PiccicaccoNick (Nicholas) Piccicacco
Nick (Nicholas) Piccicacco
MOMelissa O'Neal
Melissa O'Neal
Penicillin (PCN) allergies are frequently reported despite a true prevalence of less than 1%, leading to unnecessary avoidance of beta-lactams, broader antimicrobial use, and increased healthcare costs. Pharmacist-driven de-labeling programs offer a strategy to improve antimicrobial stewardship. This single-center, retrospective study evaluated hospitalized adults with a documented PCN allergy and screened by the pharmacist-driven penicillin allergy de-labeling service (PADLS) between 16 January and 26 June 2025. Patients were categorized into a screened cohort and a Full Allergy Reconciliation (FAR) cohort if interviewed using PEN-FAST. Eligible patients underwent direct oral challenge (DOC), penicillin skin testing (PST) plus DOC, or direct de-labeling based on PEN-FAST scoring. Sixty-three patients were screened, and 32 (50.8%) underwent full reconciliation. Among FAR patients, the median PEN-FAST score was 0, and 25 (78.1%) underwent DOC. De-labeling was successful in 28 FAR patients (87.5%). One patient (4%) experienced a mild reaction. Allergy field updates occurred in 69.8% of screened and 96.9% of FAR patients. Antibiotic optimization occurred in 12 FAR patients, saving 78 days of therapy. Estimated cost savings totaled $37,632. PADLS effectively and safely de-labeled PCN allergies, resulting in improved antimicrobial selection, and could generate cost savings, supporting broader implementation of pharmacist-led allergy stewardship programs.

25 September 2026 in Antimicrobial Stewardship & Healthcare Epidemiology
Verified
Journal Article
Open access
PDF file
CDChad Michael Dittmar
Chad Michael Dittmar
ACAlexander Coughlin
Alexander Coughlin
MOMelissa O'Neal
Melissa O'Neal
Nick (Nicholas) PiccicaccoNick (Nicholas) Piccicacco
Nick (Nicholas) Piccicacco
KGKristen Greene
Kristen Greene
In this study of adult patients with uncomplicated Enterobacterales bloodstream infections, the median duration of antibiotic therapy was 12.3 days (IQR 9.6, 15). Compared to current literature, most patients had opportunities for shorter durations of therapy. Opportunities exist for antimicrobial stewardship programs to optimize antibiotic use for these infections.